Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

JBT-101 · IP751, CPL-7075

Small molecule · developed by Corbus Pharmaceuticals

Phase 3 Most advanced trial (none active)

CRBP Developer

3 Registered trials

What is JBT-101?

JBT-101 is an orally administered agent studied in cystic fibrosis, systemic lupus erythematosus and dermatomyositis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: IP751, CPL-7075, lenabasum, anabasum, resunab, ajulemic acid
Drug type: Small molecule
Therapy area: Immunology, Respiratory
Developer: Corbus Pharmaceuticals Inc. (CRBP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: OGN7X90BT8

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03813160	Phase 3	Dermatomyositis	Completed	CRBP
NCT03093402	Phase 2	Systemic Lupus Erythematosus	Completed	CRBP
NCT02465450	Phase 2	Cystic Fibrosis	Completed	CRBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic FibrosisDermatomyositisLupusSLESystemic Lupus Erythematosus

More from Corbus Pharmaceuticals

CRB-601 Phase 1/2 CRB-913 Phase 1 Extension Phase 2 Sutantatug Envedotin Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CRBP page.

Follow CRBP, the company behind JBT-101

See CRBP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRBP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z